A rational roadmap for SARS‐CoV‐2/COVID‐19 pharmacotherapeutic research and development: IUPHAR Review 29

In this review, we identify opportunities for drug discovery in the treatment of COVID‐19 and, in so doing, provide a rational roadmap whereby pharmacology and pharmacologists can mitigate against the global pandemic. We assess the scope for targeting key host and viral targets in the mid‐term, by first screening these targets against drugs already licensed, an agenda for drug repurposing, which should allow rapid translation to clinical trials. A simultaneous, multi‐pronged approach using conventional drug discovery methods aimed at discovering novel chemical and biological means of targeting a short list of host and viral entities which should extend the arsenal of anti‐SARS‐CoV‐2 agents. This longer term strategy would provide a deeper pool of drug choices for future‐proofing against acquired drug resistance. Second, there will be further viral threats, which will inevitably evade existing vaccines. This will require a coherent therapeutic strategy which pharmacology and pharmacologists are best placed to provide.

[1]  M. Peitsch,et al.  Cloning of the TMPRSS2 gene, which encodes a novel serine protease with transmembrane, LDLRA, and SRCR domains and maps to 21q22.3. , 1997, Genomics.

[2]  F. Krammer,et al.  SARS-CoV-2 Vaccines: Status Report , 2020, Immunity.

[3]  N. Kabbani,et al.  Is nicotine exposure linked to cardiopulmonary vulnerability to COVID‐19 in the general population? , 2020, The FEBS journal.

[4]  Jason Mercer,et al.  Lipid interactions during virus entry and infection , 2014, Cellular microbiology.

[5]  E. Latz,et al.  Targeting the NLRP3 inflammasome in inflammatory diseases , 2018, Nature Reviews Drug Discovery.

[6]  S. Zhang,et al.  Neutralization of SARS-CoV-2 spike pseudotyped virus by recombinant ACE2-Ig , 2020, Nature Communications.

[7]  G. Lippi,et al.  Cardiac troponin I in patients with coronavirus disease 2019 (COVID-19): Evidence from a meta-analysis , 2020, Progress in Cardiovascular Diseases.

[8]  Leiliang Zhang,et al.  Spike protein recognition of mammalian ACE2 predicts the host range and an optimized ACE2 for SARS-CoV-2 infection , 2020, Biochemical and Biophysical Research Communications.

[9]  E. Holmes,et al.  Genomic characterisation and epidemiology of 2019 novel coronavirus: implications for virus origins and receptor binding , 2020, The Lancet.

[10]  Wayne T. Nicholson,et al.  Deployment of convalescent plasma for the prevention and treatment of COVID-19. , 2020, The Journal of clinical investigation.

[11]  E. Latz,et al.  Targeting the NLRP3 inflammasome in inflammatory diseases , 2018, Nature Reviews Drug Discovery.

[12]  T. Sasazuki,et al.  Modulation of TNF-α-converting enzyme by the spike protein of SARS-CoV and ACE2 induces TNF-α production and facilitates viral entry , 2008, Proceedings of the National Academy of Sciences.

[13]  P. Shao,et al.  Fenofibrate down-regulates the expressions of androgen receptor (AR) and AR target genes and induces oxidative stress in the prostate cancer cell line LNCaP. , 2013, Biochemical and biophysical research communications.

[14]  C. M. Petit,et al.  Palmitoylation of the cysteine-rich endodomain of the SARS–coronavirus spike glycoprotein is important for spike-mediated cell fusion , 2006, Virology.

[15]  Z. Rao,et al.  Structure of the Main Protease from a Global Infectious Human Coronavirus, HCoV-HKU1 , 2008, Journal of Virology.

[16]  Wei Lu,et al.  Severe acute respiratory syndrome-associated coronavirus 3a protein forms an ion channel and modulates virus release , 2006, Proceedings of the National Academy of Sciences.

[17]  Robert Ménard,et al.  Selectivity in ISG15 and ubiquitin recognition by the SARS coronavirus papain-like protease , 2007, Archives of Biochemistry and Biophysics.

[18]  G. Whittaker,et al.  Activation of the SARS coronavirus spike protein via sequential proteolytic cleavage at two distinct sites , 2009, Proceedings of the National Academy of Sciences.

[19]  G. Herrler,et al.  SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor , 2020, Cell.

[20]  D. Jans,et al.  The FDA-approved drug ivermectin inhibits the replication of SARS-CoV-2 in vitro , 2020, Antiviral Research.

[21]  R. Hubert,et al.  Catalytic cleavage of the androgen-regulated TMPRSS2 protease results in its secretion by prostate and prostate cancer epithelia. , 2001, Cancer research.

[22]  Sung Keun Kang,et al.  Molecular evolution of the SARS coronavirus during the course of the SARS epidemic in China. , 2004, Science.

[23]  Masahiro Morita,et al.  La-related Protein 1 (LARP1) Represses Terminal Oligopyrimidine (TOP) mRNA Translation Downstream of mTOR Complex 1 (mTORC1)* , 2015, The Journal of Biological Chemistry.

[24]  M. Ascano,et al.  G3BP1 enhances cytoplasmic DNA pattern recognition , 2018, Nature Immunology.

[25]  Christian Drosten,et al.  Dipeptidyl peptidase 4 is a functional receptor for the emerging human coronavirus-EMC , 2013, Nature.

[26]  G. Gao,et al.  A Novel Coronavirus from Patients with Pneumonia in China, 2019 , 2020, The New England journal of medicine.

[27]  B. Neuman,et al.  Severe Acute Respiratory Syndrome Coronavirus Nonstructural Proteins 3, 4, and 6 Induce Double-Membrane Vesicles , 2013, mBio.

[28]  K. Pavelić,et al.  Novel 1,2,4-triazole and imidazole derivatives of L-ascorbic and imino-ascorbic acid: synthesis, anti-HCV and antitumor activity evaluations. , 2012, Bioorganic & Medicinal Chemistry.

[29]  B. Morris,et al.  No association of Angiotensin-Converting enzyme 2 gene (ACE2) polymorphisms with essential hypertension , 2004, American Journal of Hypertension.

[30]  J. M. Melancon,et al.  Genetic analysis of the SARS-coronavirus spike glycoprotein functional domains involved in cell-surface expression and cell-to-cell fusion , 2005, Virology.

[31]  D. Falzarano,et al.  SARS and MERS: recent insights into emerging coronaviruses , 2016, Nature Reviews Microbiology.

[32]  F. Beau,et al.  Development of potent and selective phosphinic peptide inhibitors of angiotensin-converting enzyme 2. , 2008, Journal of medicinal chemistry.

[33]  Y. Guan,et al.  Unique and Conserved Features of Genome and Proteome of SARS-coronavirus, an Early Split-off From the Coronavirus Group 2 Lineage , 2003, Journal of Molecular Biology.

[34]  L. Burrell,et al.  Angiotensin‐converting enzyme 2 catalytic activity in human plasma is masked by an endogenous inhibitor , 2008, Experimental physiology.

[35]  Ying Wang,et al.  COVID-19 infection: the perspectives on immune responses , 2020, Cell Death & Differentiation.

[36]  D. Hui,et al.  ACE2 Gene Polymorphisms Do Not Affect Outcome of Severe Acute Respiratory Syndrome , 2004, Clinical chemistry.

[37]  K. Robison,et al.  A Novel Angiotensin-Converting Enzyme–Related Carboxypeptidase (ACE2) Converts Angiotensin I to Angiotensin 1-9 , 2000, Circulation research.

[38]  S. Pascarella,et al.  COVID‐2019: The role of the nsp2 and nsp3 in its pathogenesis , 2020, Journal of medical virology.

[39]  Alain Le Coupanec,et al.  Human Coronaviruses and Other Respiratory Viruses: Underestimated Opportunistic Pathogens of the Central Nervous System? , 2019, Viruses.

[40]  Wei Feng,et al.  Trend and forecasting of the COVID-19 outbreak in China , 2020, Journal of Infection.

[41]  Timothy B. Stockwell,et al.  Infidelity of SARS-CoV Nsp14-Exonuclease Mutant Virus Replication Is Revealed by Complete Genome Sequencing , 2010, PLoS pathogens.

[42]  J. R.,et al.  Quantitative analysis , 1892, Nature.

[43]  J. Torres,et al.  Structure and Inhibition of the SARS Coronavirus Envelope Protein Ion Channel , 2009, PLoS pathogens.

[44]  Dong-Yan Jin,et al.  A tug-of-war between severe acute respiratory syndrome coronavirus 2 and host antiviral defence: lessons from other pathogenic viruses , 2020, Emerging microbes & infections.

[45]  Jiyuan Zhang,et al.  Pathological findings of COVID-19 associated with acute respiratory distress syndrome , 2020, The Lancet Respiratory Medicine.

[46]  Z. Memish,et al.  Treatment of Middle East respiratory syndrome with a combination of lopinavir/ritonavir and interferon-β1b (MIRACLE trial): statistical analysis plan for a recursive two-stage group sequential randomized controlled trial , 2020, Trials.

[47]  M. D. De Buyzere,et al.  The host’s angiotensin-converting enzyme polymorphism may explain epidemiological findings in COVID-19 infections , 2020, Clinica Chimica Acta.

[48]  Andreas Sewing,et al.  Development and Automation of a 384-Well Cell Fusion Assay to Identify Inhibitors of CCR5/CD4-Mediated HIV Virus Entry , 2004, Journal of biomolecular screening.

[49]  J. Torres,et al.  Conductance and amantadine binding of a pore formed by a lysine-flanked transmembrane domain of SARS coronavirus envelope protein , 2007, Protein science : a publication of the Protein Society.

[50]  Rolf Hilgenfeld,et al.  Nsp3 of coronaviruses: Structures and functions of a large multi-domain protein , 2017, Antiviral Research.

[51]  G. Marfany,et al.  Novel Candidate Genes and a Wide Spectrum of Structural and Point Mutations Responsible for Inherited Retinal Dystrophies Revealed by Exome Sequencing , 2016, PloS one.

[52]  A. Walls,et al.  Structure, Function, and Antigenicity of the SARS-CoV-2 Spike Glycoprotein , 2020, Cell.

[53]  Alimuddin Zumla,et al.  Coronaviruses — drug discovery and therapeutic options , 2016, Nature Reviews Drug Discovery.

[54]  Nan Li,et al.  The E3 ubiquitin ligase Nrdp1 'preferentially' promotes TLR-mediated production of type I interferon , 2009, Nature Immunology.

[55]  A. Shevchenko,et al.  Quantitative analysis of the lipidomes of the influenza virus envelope and MDCK cell apical membrane , 2012, The Journal of cell biology.

[56]  K. To,et al.  Genomic characterization of the 2019 novel human-pathogenic coronavirus isolated from a patient with atypical pneumonia after visiting Wuhan , 2020, Emerging microbes & infections.

[57]  C. Vardavas,et al.  COVID-19 and smoking: A systematic review of the evidence , 2020, Tobacco induced diseases.

[58]  E. Holmes,et al.  A new coronavirus associated with human respiratory disease in China , 2020, Nature.

[59]  Benjamin J. Polacco,et al.  A SARS-CoV-2 Protein Interaction Map Reveals Targets for Drug-Repurposing , 2020, Nature.

[60]  M. Matsumura,et al.  The androgen‐regulated type II serine protease TMPRSS2 is differentially expressed and mislocalized in prostate adenocarcinoma , 2008, The Journal of pathology.

[61]  T. Parsons,et al.  Hydrolysis of Biological Peptides by Human Angiotensin-converting Enzyme-related Carboxypeptidase* , 2002, The Journal of Biological Chemistry.

[62]  K. Krzystyniak,et al.  Entry of mouse hepatitis virus 3 into cells. , 1984, The Journal of general virology.

[63]  R. Lamb,et al.  Ion channel activity of influenza A virus M2 protein: characterization of the amantadine block , 1993, Journal of virology.

[64]  D. Newby,et al.  Acute Cardiovascular Effects of Apelin in Humans: Potential Role in Patients With Chronic Heart Failure , 2010, Circulation.

[65]  C. Yeo,et al.  Enteric involvement of coronaviruses: is faecal–oral transmission of SARS-CoV-2 possible? , 2020, The Lancet Gastroenterology & Hepatology.

[66]  Guangdi Li,et al.  Therapeutic options for the 2019 novel coronavirus (2019-nCoV) , 2020, Nature Reviews Drug Discovery.

[67]  L. Hood,et al.  Prostate-localized and androgen-regulated expression of the membrane-bound serine protease TMPRSS2. , 1999, Cancer research.

[68]  L. van der Hoek,et al.  Simultaneous Treatment of Human Bronchial Epithelial Cells with Serine and Cysteine Protease Inhibitors Prevents Severe Acute Respiratory Syndrome Coronavirus Entry , 2012, Journal of Virology.

[69]  Raymond C Stevens,et al.  Severe acute respiratory syndrome coronavirus papain-like protease: structure of a viral deubiquitinating enzyme. , 2006, Proceedings of the National Academy of Sciences of the United States of America.

[70]  M. Raizada,et al.  Structure-Based Identification of Small-Molecule Angiotensin-Converting Enzyme 2 Activators as Novel Antihypertensive Agents , 2008, Hypertension.

[71]  Hua Cai,et al.  Sex difference and smoking predisposition in patients with COVID-19 , 2020, The Lancet Respiratory Medicine.

[72]  Yu-An Huang,et al.  Synthesis, crystal structure, structure-activity relationships, and antiviral activity of a potent SARS coronavirus 3CL protease inhibitor. , 2006, Journal of medicinal chemistry.

[73]  M. Esler,et al.  Can angiotensin receptor-blocking drugs perhaps be harmful in the COVID-19 pandemic? , 2020, Journal of hypertension.

[74]  Lin Chen,et al.  Transcriptional regulation by calcium, calcineurin, and NFAT. , 2003, Genes & development.

[75]  D. Jin,et al.  A molecular arms race between host innate antiviral response and emerging human coronaviruses , 2016, Virologica Sinica.

[76]  S. Bröer,et al.  The solute carrier 6 family of transporters , 2012, British journal of pharmacology.

[77]  Alexander E Gorbalenya,et al.  Mechanisms and enzymes involved in SARS coronavirus genome expression. , 2003, The Journal of general virology.

[78]  S. Tsui,et al.  The ion channel activity of the SARS-coronavirus 3a protein is linked to its pro-apoptotic function , 2009, The International Journal of Biochemistry & Cell Biology.

[79]  Lidia V. Kulemina,et al.  Prediction of Off-Target Effects on Angiotensin-Converting Enzyme 2 , 2011, Journal of biomolecular screening.

[80]  B. Graham,et al.  Cryo-EM structure of the 2019-nCoV spike in the prefusion conformation , 2020, Science.

[81]  A. Mesecar,et al.  The SARS-coronavirus papain-like protease: Structure, function and inhibition by designed antiviral compounds , 2014, Antiviral Research.

[82]  A. Zijlstra,et al.  The membrane-anchored serine protease, TMPRSS2, activates PAR-2 in prostate cancer cells. , 2005, The Biochemical journal.

[83]  Ponraj Prabakaran,et al.  The SARS Coronavirus S Glycoprotein Receptor Binding Domain: Fine Mapping and Functional Characterization , 2005, Virology Journal.

[84]  P. Rottier,et al.  Molecular Interactions in the Assembly of Coronaviruses , 2005, Advances in Virus Research.

[85]  Guoping Zhao,et al.  Molecular Evolution of the SARS Coronavirus During the Course of the SARS Epidemic in China , 2004, Science.

[86]  D. Diz,et al.  Effect of Angiotensin-Converting Enzyme Inhibition and Angiotensin II Receptor Blockers on Cardiac Angiotensin-Converting Enzyme 2 , 2005, Circulation.

[87]  Jaume Torres,et al.  Severe acute respiratory syndrome coronavirus E protein transports calcium ions and activates the NLRP3 inflammasome , 2015, Virology.

[88]  C. Machamer,et al.  The Coronavirus E Protein: Assembly and Beyond , 2012, Viruses.

[89]  P. Daszak,et al.  Fatal swine acute diarrhoea syndrome caused by an HKU2-related coronavirus of bat origin , 2018, Nature.

[90]  S. Sriramula,et al.  Determining the Enzymatic Activity of Angiotensin-Converting Enzyme 2 (ACE2) in Brain Tissue and Cerebrospinal Fluid Using a Quenched Fluorescent Substrate. , 2017, Methods in molecular biology.

[91]  P. Nelson,et al.  The androgen-regulated protease TMPRSS2 activates a proteolytic cascade involving components of the tumor microenvironment and promotes prostate cancer metastasis. , 2014, Cancer discovery.

[92]  Yukihito Sato,et al.  [Cardiac troponin]. , 2007, Nihon rinsho. Japanese journal of clinical medicine.

[93]  R. Glen,et al.  [Pyr1]Apelin-13(1–12) Is a Biologically Active ACE2 Metabolite of the Endogenous Cardiovascular Peptide [Pyr1]Apelin-13 , 2017, Front. Neurosci..

[94]  Jian-Piao Cai,et al.  Treatment With Lopinavir/Ritonavir or Interferon-β1b Improves Outcome of MERS-CoV Infection in a Nonhuman Primate Model of Common Marmoset , 2015, The Journal of infectious diseases.

[95]  J. Turnbull,et al.  The 2019 coronavirus (SARS-CoV-2) surface protein (Spike) S1 Receptor Binding Domain undergoes conformational change upon heparin binding , 2020, bioRxiv.

[96]  P. Vidalain,et al.  A Human Coronavirus Responsible for the Common Cold Massively Kills Dendritic Cells but Not Monocytes , 2012, Journal of Virology.

[97]  A. M. Leontovich,et al.  The species Severe acute respiratory syndrome-related coronavirus: classifying 2019-nCoV and naming it SARS-CoV-2 , 2020, Nature Microbiology.

[98]  R. Depping,et al.  Controlling the Gatekeeper: Therapeutic Targeting of Nuclear Transport , 2018, Cells.

[99]  F. Weber,et al.  Interaction of SARS and MERS Coronaviruses with the Antiviral Interferon Response , 2016, Advances in Virus Research.

[100]  N. Heaton,et al.  Multifaceted roles for lipids in viral infection , 2011, Trends in Microbiology.

[101]  Bo Li,et al.  Prevalence and impact of cardiovascular metabolic diseases on COVID-19 in China , 2020, Clinical Research in Cardiology.

[102]  S. Sriramula,et al.  Clinical Relevance and Role of Neuronal AT1 Receptors in ADAM17-Mediated ACE2 Shedding in Neurogenic Hypertension , 2017, Circulation research.

[103]  Guo-Ping Zhou,et al.  Triggering the Interferon Antiviral Response Through an IKK-Related Pathway , 2003, Science.

[104]  Joy Y. Feng,et al.  The antiviral compound remdesivir potently inhibits RNA-dependent RNA polymerase from Middle East respiratory syndrome coronavirus , 2020, The Journal of Biological Chemistry.

[105]  Identification of Antiviral Drug Candidates against SARS-CoV-2 from FDA-Approved Drugs , 2020, Antimicrobial Agents and Chemotherapy.

[106]  Gaiping Zhang,et al.  Analysis of angiotensin-converting enzyme 2 (ACE2) from different species sheds some light on cross-species receptor usage of a novel coronavirus 2019-nCoV , 2020, Journal of Infection.

[107]  V. Corman,et al.  Hosts and Sources of Endemic Human Coronaviruses , 2018, Advances in Virus Research.

[108]  B. Murphy,et al.  Severe Acute Respiratory Syndrome Coronavirus Infection of Golden Syrian Hamsters , 2005, Journal of Virology.

[109]  Hualan Chen,et al.  Susceptibility of ferrets, cats, dogs, and different domestic animals to SARS-coronavirus-2 , 2020, bioRxiv.

[110]  P. Rottier,et al.  The 29-Nucleotide Deletion Present in Human but Not in Animal Severe Acute Respiratory Syndrome Coronaviruses Disrupts the Functional Expression of Open Reading Frame 8 , 2007, Journal of Virology.

[111]  Hualiang Jiang,et al.  Structure of Mpro from SARS-CoV-2 and discovery of its inhibitors , 2020, Nature.

[112]  K. Lam,et al.  The stress granule protein G3BP1 binds viral dsRNA and RIG-I to enhance interferon-β response , 2019, The Journal of Biological Chemistry.

[113]  Patrik Johansson,et al.  Structural insight into allosteric modulation of protease-activated receptor 2 , 2017, Nature.

[114]  J. Torres,et al.  Severe Acute Respiratory Syndrome Coronavirus Envelope Protein Ion Channel Activity Promotes Virus Fitness and Pathogenesis , 2014, PLoS pathogens.

[115]  S. Rehman,et al.  The SARS Coronavirus 3a protein binds calcium in its cytoplasmic domain , 2014, Virus Research.

[116]  Chris de Graaf,et al.  Advances in therapeutic peptides targeting G protein-coupled receptors , 2020, Nature Reviews Drug Discovery.

[117]  Lei Liu,et al.  Relationship between the ABO Blood Group and the COVID-19 Susceptibility , 2020, medRxiv.

[118]  Chengyu Jiang,et al.  Inhibition of SARS Pseudovirus Cell Entry by Lactoferrin Binding to Heparan Sulfate Proteoglycans , 2011, PloS one.

[119]  S. Cheley,et al.  Attenuation of murine coronavirus infection by ammonium chloride , 1985, Virology.

[120]  G. Gao,et al.  Bat-to-human: spike features determining ‘host jump’ of coronaviruses SARS-CoV, MERS-CoV, and beyond , 2015, Trends in Microbiology.

[121]  P. Nelson,et al.  Phenotypic Analysis of Mice Lacking the Tmprss2-Encoded Protease , 2006, Molecular and Cellular Biology.

[122]  Fumihiro Kato,et al.  Enhanced isolation of SARS-CoV-2 by TMPRSS2-expressing cells , 2020, Proceedings of the National Academy of Sciences.

[123]  B. Fielding,et al.  The Coronavirus Nucleocapsid Is a Multifunctional Protein , 2014, Viruses.

[124]  Lin Guo,et al.  Therapeutic Dissolution of Aberrant Phases by Nuclear-Import Receptors. , 2019, Trends in cell biology.

[125]  Arthur Christopoulos,et al.  THE CONCISE GUIDE TO PHARMACOLOGY 2019/20: Introduction and Other Protein Targets , 2019, British journal of pharmacology.

[126]  P. Gage,et al.  Amiloride derivatives block ion channel activity and enhancement of virus-like particle budding caused by HIV-1 protein Vpu , 2002, European Biophysics Journal.

[127]  J. Lescar,et al.  The Nucleocapsid Protein of Coronavirus Infectious Bronchitis Virus: Crystal Structure of Its N-Terminal Domain and Multimerization Properties , 2005, Structure.

[128]  N. Hooper,et al.  Tumor Necrosis Factor-α Convertase (ADAM17) Mediates Regulated Ectodomain Shedding of the Severe-acute Respiratory Syndrome-Coronavirus (SARS-CoV) Receptor, Angiotensin-converting Enzyme-2 (ACE2) , 2005, Journal of Biological Chemistry.

[129]  R. Lamb,et al.  Influenza A virus M2 ion channel protein: a structure-function analysis , 1994, Journal of virology.

[130]  G. Hartmann,et al.  Antiviral immunity via RIG-I-mediated recognition of RNA bearing 5′-diphosphates , 2014, Nature.

[131]  Krishna Shankara Narayanan,et al.  The Endonucleolytic RNA Cleavage Function of nsp1 of Middle East Respiratory Syndrome Coronavirus Promotes the Production of Infectious Virus Particles in Specific Human Cell Lines , 2018, Journal of Virology.

[132]  M. Lemmon,et al.  Membrane recognition by phospholipid-binding domains , 2008, Nature Reviews Molecular Cell Biology.

[133]  K. Yuen,et al.  Severe acute respiratory syndrome Coronavirus ORF3a protein activates the NLRP3 inflammasome by promoting TRAF3‐dependent ubiquitination of ASC , 2019, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[134]  S. Perlman,et al.  Coronaviruses: An Overview of Their Replication and Pathogenesis , 2015, Methods in molecular biology.

[135]  A. Mesecar,et al.  Catalytic Function and Substrate Specificity of the Papain-Like Protease Domain of nsp3 from the Middle East Respiratory Syndrome Coronavirus , 2014, Journal of Virology.

[136]  Rolf Hilgenfeld,et al.  Coronavirus Main Proteinase (3CLpro) Structure: Basis for Design of Anti-SARS Drugs , 2003, Science.

[137]  A. Mesecar,et al.  X-ray Structural and Functional Studies of the Three Tandemly Linked Domains of Non-structural Protein 3 (nsp3) from Murine Hepatitis Virus Reveal Conserved Functions , 2015, The Journal of Biological Chemistry.

[138]  W. Xue,et al.  G3BP1 promotes DNA binding and activation of cGAS , 2018, Nature Immunology.

[139]  J. Penninger,et al.  Human Recombinant ACE2 Reduces the Progression of Diabetic Nephropathy , 2009, Diabetes.

[140]  Akram Khan,et al.  A pilot clinical trial of recombinant human angiotensin-converting enzyme 2 in acute respiratory distress syndrome , 2017, Critical Care.

[141]  Josef M. Penninger,et al.  Trilogy of ACE2: A peptidase in the renin–angiotensin system, a SARS receptor, and a partner for amino acid transporters , 2010, Pharmacology & Therapeutics.

[142]  S. Diamond,et al.  Inhibitors of cathepsin L prevent severe acute respiratory syndrome coronavirus entry. , 2005, Proceedings of the National Academy of Sciences of the United States of America.

[143]  John K. Kim,et al.  LARP1 functions as a molecular switch for mTORC1-mediated translation of an essential class of mRNAs , 2017, eLife.

[144]  E. Decroly,et al.  Insights into RNA synthesis, capping, and proofreading mechanisms of SARS-coronavirus , 2014, Virus Research.

[145]  S. Xiong,et al.  The ORF4a protein of human coronavirus 229E functions as a viroporin that regulates viral production , 2013, Biochimica et Biophysica Acta (BBA) - Biomembranes.

[146]  Lisa E. Gralinski,et al.  Release of Severe Acute Respiratory Syndrome Coronavirus Nuclear Import Block Enhances Host Transcription in Human Lung Cells , 2013, Journal of Virology.

[147]  J. Bertin,et al.  Structure guided design of potent and selective ponatinib-based hybrid inhibitors for RIPK1. , 2015, Cell reports.

[148]  Jingjing Ren,et al.  G3BP1 inhibits RNA virus replication by positively regulating RIG-I-mediated cellular antiviral response , 2019, Cell Death & Disease.

[149]  Matthew Ducar,et al.  Novel Peptide Inhibitors of Angiotensin-converting Enzyme 2* , 2003, The Journal of Biological Chemistry.

[150]  Zhènglì Shí,et al.  Origin and evolution of pathogenic coronaviruses , 2018, Nature Reviews Microbiology.

[151]  B. Neuman,et al.  Inhibition of Cytosolic Phospholipase A2α Impairs an Early Step of Coronavirus Replication in Cell Culture , 2017, Journal of Virology.

[152]  K. Ishii,et al.  Differential roles of MDA5 and RIG-I helicases in the recognition of RNA viruses , 2006, Nature.

[153]  P. Masters,et al.  The Molecular Biology of Coronaviruses , 2006, Advances in Virus Research.

[154]  M. Janeczko,et al.  CK2α and CK2α' subunits differ in their sensitivity to 4,5,6,7-tetrabromo- and 4,5,6,7-tetraiodo-1H-benzimidazole derivatives. , 2012, European journal of medicinal chemistry.

[155]  A. Banham,et al.  Identification and Characterization of Peripheral T-Cell Lymphoma-Associated SEREX Antigens , 2011, PloS one.

[156]  Adam Siddiqui-Jain,et al.  Discovery and SAR of 5-(3-chlorophenylamino)benzo[c][2,6]naphthyridine-8-carboxylic acid (CX-4945), the first clinical stage inhibitor of protein kinase CK2 for the treatment of cancer. , 2011, Journal of medicinal chemistry.

[157]  Abraham J Koster,et al.  SARS-Coronavirus Replication Is Supported by a Reticulovesicular Network of Modified Endoplasmic Reticulum , 2008, PLoS biology.

[158]  Hongzhu Cui,et al.  Structural Genomics of SARS-CoV-2 Indicates Evolutionary Conserved Functional Regions of Viral Proteins , 2020, Viruses.

[159]  S. Inoue,et al.  Clathrin-Dependent Entry of Severe Acute Respiratory Syndrome Coronavirus into Target Cells Expressing ACE2 with the Cytoplasmic Tail Deleted , 2007, Journal of Virology.

[160]  A. Ullrich,et al.  Distinct ADAM Metalloproteinases Regulate G Protein-coupled Receptor-induced Cell Proliferation and Survival* , 2004, Journal of Biological Chemistry.

[161]  C. Bryant,et al.  International Union of Basic and Clinical Pharmacology. XCVI. Pattern Recognition Receptors in Health and Disease , 2015, Pharmacological Reviews.

[162]  G. Whittaker,et al.  Mechanisms of Coronavirus Cell Entry Mediated by the Viral Spike Protein , 2012, Viruses.

[163]  Q. Lin,et al.  Increased Angiotensin-(1-7)–Forming Activity in Failing Human Heart Ventricles: Evidence for Upregulation of the Angiotensin-Converting Enzyme Homologue ACE2 , 2003, Circulation.

[164]  Carson C. Thoreen,et al.  Global analysis of LARP1 translation targets reveals tunable and dynamic features of 5′ TOP motifs , 2020, Proceedings of the National Academy of Sciences.

[165]  I. Danovitch,et al.  NMDA antagonists for treating the non-motor symptoms in Parkinson’s disease , 2018, Translational Psychiatry.

[166]  A. Elfiky,et al.  Ribavirin, Remdesivir, Sofosbuvir, Galidesivir, and Tenofovir against SARS-CoV-2 RNA dependent RNA polymerase (RdRp): A molecular docking study , 2020, Life Sciences.

[167]  Wenling Wang,et al.  Age‐related rhesus macaque models of COVID‐19 , 2020, Animal models and experimental medicine.

[168]  H. Feldmann,et al.  Prophylactic and therapeutic remdesivir (GS-5734) treatment in the rhesus macaque model of MERS-CoV infection , 2020, Proceedings of the National Academy of Sciences.

[169]  KyungMann Kim,et al.  TMPRSS2, a serine protease expressed in the prostate on the apical surface of luminal epithelial cells and released into semen in prostasomes, is misregulated in prostate cancer cells. , 2010, The American journal of pathology.

[170]  H. Feldmann,et al.  The Middle East Respiratory Syndrome Coronavirus (MERS-CoV) Does Not Replicate in Syrian Hamsters , 2013, PloS one.

[171]  S. Baker,et al.  Coronavirus endoribonuclease targets viral polyuridine sequences to evade activating host sensors , 2020, Proceedings of the National Academy of Sciences.

[172]  P. Angus,et al.  Upregulation of hepatic angiotensin-converting enzyme 2 (ACE2) and angiotensin-(1–7) levels in experimental biliary fibrosis☆ , 2007, Journal of Hepatology.

[173]  Govinda Rao,et al.  IRF3 mediates a TLR3/TLR4-specific antiviral gene program. , 2002, Immunity.

[174]  M. Montenarh,et al.  Protein kinase CK2 in development and differentiation. , 2017, Biomedical reports.

[175]  N. Lee,et al.  Clinical Implications of Antiviral Resistance in Influenza , 2015, Viruses.

[176]  W. Garten,et al.  Identification of the first synthetic inhibitors of the type II transmembrane serine protease TMPRSS2 suitable for inhibition of influenza virus activation. , 2013, The Biochemical journal.

[177]  T. Kuntzweiler,et al.  Identification and Characterization of Inhibitors of a Neutral Amino Acid Transporter, SLC6A19, Using Two Functional Cell-Based Assays , 2019, SLAS discovery : advancing life sciences R & D.

[178]  Kwok-Yin Wong,et al.  Prediction of the SARS-CoV-2 (2019-nCoV) 3C-like protease (3CL pro) structure: virtual screening reveals velpatasvir, ledipasvir, and other drug repurposing candidates. , 2020, F1000Research.

[179]  Yufei Shan,et al.  Tom70 mediates activation of interferon regulatory factor 3 on mitochondria , 2010, Cell Research.

[180]  K. Burns,et al.  Measurement of Angiotensin Converting Enzyme 2 Activity in Biological Fluid (ACE2) , 2017, Methods in molecular biology.

[181]  D. Batlle,et al.  Soluble angiotensin-converting enzyme 2: a potential approach for coronavirus infection therapy? , 2020, Clinical science.

[182]  T. Steinmetzer,et al.  In vitro characterization of TMPRSS2 inhibition in IPEC-J2 cells , 2016, Journal of enzyme inhibition and medicinal chemistry.

[183]  Arthur S Slutsky,et al.  Angiotensin-converting enzyme 2 protects from severe acute lung failure , 2005, Nature.

[184]  R. Ménard,et al.  The Papain-Like Protease from the Severe Acute Respiratory Syndrome Coronavirus Is a Deubiquitinating Enzyme , 2005, Journal of Virology.

[185]  Gary R. Whittaker,et al.  Host cell proteases: Critical determinants of coronavirus tropism and pathogenesis , 2014, Virus Research.

[186]  P. Gage,et al.  SARS coronavirus E protein forms cation-selective ion channels , 2004, Virology.

[187]  C. Reis e Sousa,et al.  Cytosolic Sensing of Viruses , 2013, Immunity.

[188]  M. Clerici,et al.  Computational Inference of Selection Underlying the Evolution of the Novel Coronavirus, Severe Acute Respiratory Syndrome Coronavirus 2 , 2020, Journal of Virology.

[189]  C. Conrad,et al.  SARS-CoV-2 receptor ACE2 and TMPRSS2 are primarily expressed in bronchial transient secretory cells. , 2020, The EMBO journal.

[190]  P. Palese,et al.  Severe Acute Respiratory Syndrome Coronavirus Open Reading Frame (ORF) 3b, ORF 6, and Nucleocapsid Proteins Function as Interferon Antagonists , 2006, Journal of Virology.

[191]  Kwok-Yin Wong,et al.  Prediction of the SARS-CoV-2 (2019-nCoV) 3C-like protease (3CL pro) structure: virtual screening reveals velpatasvir, ledipasvir, and other drug repurposing candidates , 2020, F1000Research.

[192]  Nigel M. Hooper,et al.  A Human Homolog of Angiotensin-converting Enzyme , 2000, The Journal of Biological Chemistry.

[193]  Qiang Zhou,et al.  Structural basis for the recognition of SARS-CoV-2 by full-length human ACE2 , 2020, Science.

[194]  P. Nelson,et al.  Influenza and SARS-Coronavirus Activating Proteases TMPRSS2 and HAT Are Expressed at Multiple Sites in Human Respiratory and Gastrointestinal Tracts , 2012, PloS one.

[195]  C. Craik,et al.  Substrate specificity profiling and identification of a new class of inhibitor for the major protease of the SARS coronavirus. , 2007, Biochemistry.

[196]  G. Díaz-Araya,et al.  Enalapril Attenuates Downregulation of Angiotensin-Converting Enzyme 2 in the Late Phase of Ventricular Dysfunction in Myocardial Infarcted Rat , 2006, Hypertension.

[197]  Kiira Ratia,et al.  Structural Basis for the Ubiquitin-Linkage Specificity and deISGylating Activity of SARS-CoV Papain-Like Protease , 2014, PLoS pathogens.

[198]  B. Coutard,et al.  Coronavirus Nonstructural Protein 16 Is a Cap-0 Binding Enzyme Possessing (Nucleoside-2′O)-Methyltransferase Activity , 2008, Journal of Virology.

[199]  I. Nishio,et al.  [Angiotensin I converting enzyme]. , 1999, Nihon rinsho. Japanese journal of clinical medicine.

[200]  Jiachen Sun,et al.  A guideline for homology modeling of the proteins from newly discovered betacoronavirus, 2019 novel coronavirus (2019‐nCoV) , 2020, Journal of medical virology.

[201]  W. Filipowicz,et al.  ADP-Ribose-1"-Monophosphatase: a Conserved Coronavirus Enzyme That Is Dispensable for Viral Replication in Tissue Culture , 2005, Journal of Virology.

[202]  P. Nelson,et al.  Tmprss2 Is Essential for Influenza H1N1 Virus Pathogenesis in Mice , 2013, PLoS pathogens.

[203]  N. Hacohen,et al.  Peroxisomes Are Signaling Platforms for Antiviral Innate Immunity , 2010, Cell.

[204]  Cheng-Chang Chen,et al.  ORF8a of SARS-CoV forms an ion channel: Experiments and molecular dynamics simulations , 2010, Biochimica et Biophysica Acta (BBA) - Biomembranes.

[205]  Fabian J Theis,et al.  SARS-CoV-2 Receptor ACE2 Is an Interferon-Stimulated Gene in Human Airway Epithelial Cells and Is Detected in Specific Cell Subsets across Tissues , 2020, Cell.

[206]  P. Nelson,et al.  TMPRSS2 Is a Host Factor That Is Essential for Pneumotropism and Pathogenicity of H7N9 Influenza A Virus in Mice , 2014, Journal of Virology.

[207]  Jingyun Ma,et al.  Swine acute diarrhea syndrome coronavirus (SADS-CoV) antagonizes interferon-β production via blocking IPS-1 and RIG-I , 2019, Virus Research.

[208]  Zhènglì Shí,et al.  The crystal structure of COVID-19 main protease in complex with an inhibitor N3 , 2020 .

[209]  David Shum,et al.  Identification of Antiviral Drug Candidates against SARS-CoV-2 from FDA-Approved Drugs , 2020, Antimicrobial Agents and Chemotherapy.

[210]  Adam J Pawson,et al.  A rational roadmap for SARS-CoV-2/COVID-19 pharmacotherapeutic research and development , 2020 .

[211]  Robert Kleta,et al.  Tissue-Specific Amino Acid Transporter Partners ACE2 and Collectrin Differentially Interact With Hartnup Mutations , 2008, Gastroenterology.

[212]  M. Schlee.  Master sensors of pathogenic RNA – RIG-I like receptors , 2013, Immunobiology.

[213]  S. Bröer,et al.  Intestinal peptidases form functional complexes with the neutral amino acid transporter B0AT1 , 2012, The Biochemical journal.

[214]  J. Tchinda,et al.  Recurrent Fusion of TMPRSS2 and ETS Transcription Factor Genes in Prostate Cancer , 2005, Science.

[215]  C. Wang,et al.  Synthesis and immunosuppressive activity of some side-chain variants of mycophenolic acid. , 1990, Journal of medicinal chemistry.

[216]  Serum activity of angiotensin converting enzyme 2 is decreased in patients with acute ischemic stroke , 2016, Journal of the renin-angiotensin-aldosterone system : JRAAS.

[217]  Thanigaimalai Pillaiyar,et al.  Recent discovery and development of inhibitors targeting coronaviruses , 2020, Drug Discovery Today.

[218]  J. Penninger,et al.  Angiotensin-Converting Enzyme 2 Suppresses Pathological Hypertrophy, Myocardial Fibrosis, and Cardiac Dysfunction , 2010, Circulation.

[219]  Baoying Huang,et al.  Susceptibility of ferrets, cats, dogs, and other domesticated animals to SARS–coronavirus 2 , 2020, Science.

[220]  Zhènglì Shí,et al.  Inhibition of SARS-CoV-2 (previously 2019-nCoV) infection by a highly potent pan-coronavirus fusion inhibitor targeting its spike protein that harbors a high capacity to mediate membrane fusion , 2020, Cell Research.

[221]  Zhongbin Chen,et al.  Proteolytic processing, deubiquitinase and interferon antagonist activities of Middle East respiratory syndrome coronavirus papain-like protease. , 2014, The Journal of general virology.

[222]  K. Konan,et al.  Sphingolipids as Potential Therapeutic Targets against Enveloped Human RNA Viruses , 2019, Viruses.

[223]  James E. Bradner,et al.  Chemical Phylogenetics of Histone Deacetylases , 2010, Nature chemical biology.

[224]  Mones Abu-Asab,et al.  SARS-Coronavirus Open Reading Frame-9b Suppresses Innate Immunity by Targeting Mitochondria and the MAVS/TRAF3/TRAF6 Signalosome , 2014, The Journal of Immunology.

[225]  A. Look,et al.  Human aminopeptidase N is a receptor for human coronavirus 229E , 1992, Nature.

[226]  Zhongbin Chen,et al.  The Papain-Like Protease of Severe Acute Respiratory Syndrome Coronavirus Has Deubiquitinating Activity , 2005, Journal of Virology.

[227]  J. Ziebuhr,et al.  Human Coronavirus 229E Papain-Like Proteases Have Overlapping Specificities but Distinct Functions in Viral Replication , 2007, Journal of Virology.

[228]  Trey Ideker,et al.  A SARS-CoV-2-Human Protein-Protein Interaction Map Reveals Drug Targets and Potential Drug-Repurposing , 2020, bioRxiv.

[229]  K. List,et al.  The role of type II transmembrane serine protease‐mediated signaling in cancer , 2017, The FEBS journal.

[230]  R. Deschenes,et al.  DHHC9 and GCP16 Constitute a Human Protein Fatty Acyltransferase with Specificity for H- and N-Ras* , 2005, Journal of Biological Chemistry.

[231]  M. Crackower,et al.  Angiotensin-converting enzyme 2 is an essential regulator of heart function , 2002, Nature.

[232]  B. Hogue,et al.  Importance of Conserved Cysteine Residues in the Coronavirus Envelope Protein , 2008, Journal of Virology.

[233]  J. Rasko,et al.  A protein complex in the brush‐border membrane explains a Hartnup disorder allele , 2008, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[234]  Mark Chappell,et al.  A crucial role of angiotensin converting enzyme 2 (ACE2) in SARS coronavirus–induced lung injury , 2005, Nature Medicine.

[235]  S. Harrison,et al.  Structure of SARS Coronavirus Spike Receptor-Binding Domain Complexed with Receptor , 2005, Science.

[236]  J. Torres,et al.  MERS coronavirus envelope protein has a single transmembrane domain that forms pentameric ion channels , 2015, Virus Research.

[237]  Hassan Mohammad Naif,et al.  Potential New Anti-Human Immunodeficiency Virus Type 1 Compounds Depress Virus Replication in Cultured Human Macrophages , 2004, Antimicrobial Agents and Chemotherapy.

[238]  R. Hilgenfeld,et al.  α-Ketoamides as Broad-Spectrum Inhibitors of Coronavirus and Enterovirus Replication: Structure-Based Design, Synthesis, and Activity Assessment , 2020, Journal of medicinal chemistry.

[239]  T. Greenough,et al.  Therapy with a Severe Acute Respiratory Syndrome–Associated Coronavirus–Neutralizing Human Monoclonal Antibody Reduces Disease Severity and Viral Burden in Golden Syrian Hamsters , 2006, The Journal of infectious diseases.

[240]  John Bechill,et al.  Identification of Severe Acute Respiratory Syndrome Coronavirus Replicase Products and Characterization of Papain-Like Protease Activity , 2004, Journal of Virology.

[241]  J. Penninger,et al.  B38-CAP is a bacteria-derived ACE2-like enzyme that suppresses hypertension and cardiac dysfunction , 2020, Nature Communications.

[242]  P. Mehta,et al.  COVID-19: consider cytokine storm syndromes and immunosuppression , 2020, The Lancet.

[243]  Lawrence H. Pinto,et al.  Influenza virus M2 protein has ion channel activity , 1992, Cell.

[244]  G. von Heijne,et al.  Tissue-based map of the human proteome , 2015, Science.

[245]  Chuan Qin,et al.  From SARS to MERS, Thrusting Coronaviruses into the Spotlight , 2019, Viruses.

[246]  A. Danchin,et al.  The Severe Acute Respiratory Syndrome , 2003 .

[247]  Xuhong Song,et al.  Androgen Receptor-Activated Enhancers Simultaneously Regulate Oncogene TMPRSS2 and lncRNA PRCAT38 in Prostate Cancer , 2019, Cells.

[248]  T. Maniatis,et al.  IKKε and TBK1 are essential components of the IRF3 signaling pathway , 2003, Nature Immunology.

[249]  S. Perlman,et al.  Coronaviruses post-SARS: update on replication and pathogenesis , 2009, Nature Reviews Microbiology.

[250]  F. C. Knoop,et al.  Influenza A , 2007, xPharm: The Comprehensive Pharmacology Reference.

[251]  C. Schwegmann-Wessels,et al.  Importance of cholesterol-rich membrane microdomains in the interaction of the S protein of SARS-coronavirus with the cellular receptor angiotensin-converting enzyme 2 , 2008, Virology.

[252]  Christian Drosten,et al.  The SARS-Coronavirus-Host Interactome: Identification of Cyclophilins as Target for Pan-Coronavirus Inhibitors , 2011, PLoS pathogens.

[253]  Andrea Marzi,et al.  Functional assessment of cell entry and receptor usage for SARS-CoV-2 and other lineage B betacoronaviruses , 2020, Nature Microbiology.